- Home
- MRVI vs VLGEA Comparison
MRVI vs VLGEA Comparison
Compare MRVI & VLGEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRVI
- VLGEA
- Stock Information
- Founded
- MRVI 2014
- VLGEA 1937
- Country
- MRVI United States
- VLGEA United States
- Employees
- MRVI N/A
- VLGEA N/A
- Industry
- MRVI Biotechnology: Pharmaceutical Preparations
- VLGEA Food Chains
- Sector
- MRVI Health Care
- VLGEA Consumer Staples
- Exchange
- MRVI Nasdaq
- VLGEA Nasdaq
- Market Cap
- MRVI 262.9M
- VLGEA N/A
- IPO Year
- MRVI 2020
- VLGEA N/A
- Fundamental
- Price
- MRVI $2.05
- VLGEA $35.39
- Analyst Decision
- MRVI Hold
- VLGEA
- Analyst Count
- MRVI 9
- VLGEA 0
- Target Price
- MRVI $6.54
- VLGEA N/A
- AVG Volume (30 Days)
- MRVI 2.6M
- VLGEA 56.2K
- Earning Date
- MRVI 05-07-2025
- VLGEA 06-03-2025
- Dividend Yield
- MRVI N/A
- VLGEA 2.86%
- EPS Growth
- MRVI N/A
- VLGEA 3.71
- EPS
- MRVI N/A
- VLGEA 3.65
- Revenue
- MRVI $259,185,000.00
- VLGEA $2,281,980,000.00
- Revenue This Year
- MRVI N/A
- VLGEA N/A
- Revenue Next Year
- MRVI $14.23
- VLGEA N/A
- P/E Ratio
- MRVI N/A
- VLGEA $9.70
- Revenue Growth
- MRVI N/A
- VLGEA 3.96
- 52 Week Low
- MRVI $1.67
- VLGEA $24.57
- 52 Week High
- MRVI $11.56
- VLGEA $38.70
- Technical
- Relative Strength Index (RSI)
- MRVI 44.60
- VLGEA 50.55
- Support Level
- MRVI $1.67
- VLGEA $34.20
- Resistance Level
- MRVI $2.21
- VLGEA $36.52
- Average True Range (ATR)
- MRVI 0.16
- VLGEA 1.29
- MACD
- MRVI 0.08
- VLGEA -0.14
- Stochastic Oscillator
- MRVI 70.37
- VLGEA 33.33
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.